Product Description: NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively[1].
Applications: Cancer-Kinase/protease
Formula: C27H28F2N6O
Citations: Bioorg Chem. 2024 Apr 29:147:107412./Patent. US20180263995A1./Pharmaceuticals. 2024 May 14;17(5):631.
References: [1]Baffert F, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther. 2010 Jul;9(7):1945-55./[2]Cheon JH, et al. The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine. Biochem Biophys Res Commun. 2017 Sep 2;490(4):1176-1182.
CAS Number: 1092499-93-8
Molecular Weight: 490.55
Compound Purity: 99.89
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: JAK
English
Deutsch
